The Comprehensive
Digestive Stool Analysis (CDSA) is the original non-invasive evaluation of gastrointestinal function that includes
analyses of digestion, absorption, bacterial balance, yeast and parasites. This profile is recommended for patients with
diffuse and non-specific GI-related symptoms, such as indigestion, dysbiosis, constipation, and diarrhea.
Comprehensive
Digestive Stool Analysis (CDSA) 2.0 uses advanced GI biotechnology to evaluate digestion, absorption, pancreatic
function, and inflammation, in addition to bacterial balance, yeast, and parasite infection. This profile features exclusive
new markers for assessing irritable bowel syndrome, sub-mucosal inflammation, colorectal cancer risk, pancreatic insufficiency,
and occult infection.
Comprehensive Parasitology
Profile evaluates stool for presence of parasites and levels of beneficial flora, imbalanced flora, pathogenic bacteria,
and yeast. For patients with abdominal pain, chronic diarrhea, and other GI-related symptoms.
Intestinal Permeability
Assessment analyzes urine for the clearance of two non-metabolized sugars, lactulose and mannitol. Identifies "leaky gut"
and malabsorption.
Lactose Intolerance
Breath Test is a simple, noninvasive test, detects lactose intolerance, a condition affecting more than 50 million
Americans. Proper detection enables effective treatment of lactose maldigestion and malabsorption to help alleviate chronic
symptoms of bloating, gas, diarrhea, and abdominal pain.
Bacterial
Overgrowth of the Small Intestine Breath Test is a simple, noninvasive test that detects bacterial overgrowth in the
small intestine, a common condition that often underlies chronic symptoms of maldigestion and malabsorption, including bloating,
gas, diarrhea, irregularity, and abdominal pain.
Heliobacter pylori Stool Antigen Test is an FDA - approved evaluation of H. pylori antigens shed directly in the stool. This test is useful for
detecting the major causal bacterium associated with peptic ulcers, chronic gastritis, and increased risk of gastric cancer. This
noninvasive test also provides a simple and sensitive clinical tool for monitoring eradication therapy.
Vaginosis Profile
uses a new DNA probe to identify clinically significant levels of Candida, Gardnerella, and Trichomonas. The profile also evaluates
levels of beneficial flora and yeast, cytosis, leukocytes, and RBCs. A measurement of eosinophils may also be included.
